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Abstract 
 
Introduction 
	
HIV is not only a health problem but also as a socio-economic and development problem. 
Treatment failure contributes to development of drug resistance, the risk of transmission 
increase and inadequate treatment leads to death. Herbal medicines are sometimes used as a 
primary treatment for HIV/AIDS and HIV-related problems. It has been shown that herbal 
medications effect the serum levels of antiretroviral medications. Up to 80% use herbal 
medication in some parts of Africa. Stigma and the discrimination of people living with HIV 
are some of the biggest challenges when it comes to HIV prevention, treatment, care and 
support.  
Aim 
 
The aim of the study was to identify factors that are associated with therapy failure at 
Dodoma Regional Hospital, Tanzania.  
Methods 
 
Data was collected of 93 HIV-diagnosed men and women at Dodoma Regional Hospital, 
Tanzania. Treatment failure was determined following the WHO criteria for clinical and 
immunological treatment failure with some modification. SPSS were used to compare patients 
with successful treatment to patients failing treatment. In cases were a significant P-value was 
found the two groups were compared with odds ratios with 95 % confidence intervals for the 
underlying factors and outcome variables. 
  
		
Results 
 
Among the 93 patients, 77% were women and 23% were men and the mean age was 44 years. 
The prevalence of treatment failure among the patients monitored at the hospital was 15%. 
High transport costs (OR 5.74), long time traveling to the clinics (OR 11.26), and the advice 
from traditional healers to stop antiretroviral treatment (OR 40.8), were found to be 
significant predictors of treatment failure.  
Conclusions 
 
Long travels to the hospitals, high transport costs and advice from traditional healers to stop  
 
using antiretroviral treatment were factors associated with an increased risk of therapy failure.  
Keywords 
 
HIV, treatment failure, antiretroviral drugs, traditional healer. 
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1. Introduction  
	
1.1 Background 
	
1.1.1 Epidemiology 
	
Approximately 36.6 million people around the world are estimated living with HIV. Around 
2.1 million are annually getting infected by HIV and about 1.1 million people die from AIDS-
related illnesses. Low - middle income areas have the highest prevalence of HIV. 
Approximate 70 % of all people with HIV live in sub-Saharan regions where 65 % of new 
infections occur (1). 
 
1.1.2 HIV 
 
HIV (human immunodeficiency virus), is a retrovirus which has the ability to transform its 
RNA to DNA by using reverse transcriptase (RT). 
HIV infects cells in the immune system by attaching to the CD4 receptor and co-receptors, 
found on the surface of T-helper cells, macrophages, langerhans cells and microglial cells. 
After the attachment, HIV can penetrate the cells, and the transcription of viral RNA begins.  
RT then transforms the RNA to DNA and another enzyme, integrase incorporate the DNA 
into the human genome. 
 
New viruses can be produced in the infected cells by using the translation and transcription 
systems in the host cell. Proteases are important enzymes that cut the HIV-precursors to 
functional viral protein. 
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The presence of HIV strongly activates the immune system and a great loss of T-helper- and 
other immune cells are seen in HIV-positive patients due to apoptosis of the cells (2). 
 
1.1.3 AIDS  
 
The CD4 positive cells of the immune system plays an important role in fighting infections 
and some types of cancers. Therefore, a great loss of the CD4 cells results in immune 
deficiency. Untreated HIV gradually destroys the immune system and the HIV infection 
advances to AIDS (acquired immunodeficiency syndrome) which is the most advanced stage 
of HIV (3). 
 
When diagnosed with AIDS the patient’s immune system is badly damaged and opportunistic 
infections occurs. The diagnosis of AIDS is confirmed when a person with HIV infection gets 
one or more of the severe opportunistic infections or malignancies, for instance Kaposi 
sarcoma, cryptococcal meningitis, invasive cervical cancer, toxoplasmosis and CMV retinitis. 
This stage is equal with WHO stage 4 (4). AIDS leads to death if untreated (5). 
 
1.1.4 Transmission of HIV 
 
The most common cause of HIV transmission is sexual intercourse and HIV can be 
transmitted when practising anal, oral and vaginal sex without using condom, with a higher 
risk of getting an infection practicing anal sex. HIV can also be transmitted through blood and 
blood products, dirty needles and from mother to child transmission during pregnancy, 
childbirth and breast-feeding. Half of all new infections are transmitted from a newly infected 
person and the reason for this is a high viral load the first months after infection (2).  
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1.1.5 Antiretroviral treatment  
 
HIV can’t be cured. Antiretroviral treatment (ART) supress the viral replication so that people 
with HIV can live a long and healthy life and reduce the risk of transmission (1).  
Optimized treatment suppresses HIV-RNA load in plasma from 10^5-10^6 to <20 copies/ml 
Successful antiretroviral treatment results in lower viral loads allowing recovering of the 
immune system with an increase of the CD4 count. An important aspect of successful 
treatment of HIV is medication adherence. Medicament has to be taken at the right time every 
day to keep antiretroviral drug concentrations optimized and to prevent development of drug 
resistance. Patients with drug resistance have a higher risk of transmitting HIV due to higher 
viral load (2). All patients with confirmed HIV are recommended to initiate antiretroviral 
treatment, regardless of WHO clinical stage and at any CD4 cell count (6). 
 
ART can be divided into 6 groups, NRTI (Nucleoside Reverse Transcriptase Inhibitor), 
NNRTI (Non-nucleoside reverse-transcriptase inhibitors), protease inhibitors (PI), integrase 
inhibitors, fusion inhibitors and CCR5 antagonists. HIV is most often treated with 3 different 
medications, usually from two different groups (2). Combining antiretroviral drugs supresses 
HIV-replication to lower levels and is less likely to develop drug resistance compared to 
monotherapy (7). In Tanzania 4 groups are available for use, (NRTIs), (NNRTIs), Nucleotide 
reverse transcriptase inhibitors (Nucleotide analogues) and protease inhibitors (Pl) (4). Since 
2004, Tanzania offers free ART to HIV patients (8). 
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1.1.6 Impact of HIV and AIDS in sub-Saharan Africa 
 
The HIV pandemic has had a big impact in the world, especially in the sub Saharan-Africa. 
The effect of the high prevalence of HIV in the area has resulted in restricted resources for 
other medical conditions. In Tanzania bed occupancy rate for HIV-positive patients in the 
bigger regional hospitals are estimated to 50-60%. Since some in the health care staff are 
HIV-positive as well there is lack of human resources at all health care facilities (4). 
 
HIV is not only a health concern, but also as a socio-economic and development problem.   
HIV and AIDS has negatively affected economic growth (4). 
Stigma and the discrimination of people with HIV are some of the biggest challenges when it 
comes to HIV prevention, treatment, care and support. Research shows that stigma is the 
reason why many patients don’t seek treatment for HIV, disclose their HIV status to partners / 
family members and don’t seek for information about HIV. Fear of violence and exclusion 
from the society are important reasons why HIV-patients keep a low profile when it comes to 
disclosing their HIV-status or getting their medications (9).  
 
1.1.7 HIV in Tanzania 
 
n 2015, approximate 1,400,000 people were living with HIV in Tanzania with an estimated 
prevalence rate of 4.7 % among adults aged 15-49 (10). The HIV prevalence varies regionally 
from 0.2 percent (Zanzibar) to 15.4 percent (Njombe) (11). Women accounted for 60% of the 
people living with HIV aged 15 or more (10). About 36,000 people die in AIDS related 
illnesses annually (11). Unprotected sex with infected partners account for more than 90% of 
HIV-infected in Sub-Saharan Africa including Tanzania (4).  
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1.1.8 Dodoma   
 
The research was performed in Dodoma Regional Hospital situated in Dodoma. 
Dodoma is the capital of Tanzania with a population of approximate 2.1 million people. The 
prevalence of HIV among adults aged 15-49 in the region was estimated to 2.9%, 2012 (12).  
 
1.1.9 HIV monitoring, responses and therapy failure 
 
There are 3 types of therapy failure defined by WHO (World Health Organization), viral-, 
immunological- and clinical failure (13). HIV can be monitored measuring viral loads, CD4 
count and clinically. Measuring viral load is considered to be a more sensitive indicator of 
therapy failure compared to the immunological and clinical definitions.  However, there is a 
limitation of accessibility of viral load testing in low income countries (14). 
 
 According to a review the current WHO criteria for immunological and clinical failure have 
low sensitivity and positive predictive value for identifying virological failure in individuals 
(13).  
 
A study made in Tanzania included 2,403 patients and out of these 14.9 % had virological 
failure (15). Another study conducted in Tanzania included 243,844 patients from 348 clinics, 
7% experienced immunological treatment failure (16). 
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1.1.10 HIV-testing and monitoring in Tanzania 
 
Confirmation of HIV-diagnosis in adults and children > 18 years are usually done by 
detecting antibodies using two rapid tests or Enzyme Immunoassays (EIA) in whole blood, 
serum or plasma (4). 
 
Because of limited ability to use viral load testing CD4 monitoring has frequently been used 
for monitoring the disease. Clinical and immunological monitoring are used to determine 
ART eligibility and treatment response. CD4 count is measured every 6 months. For adults 
the CD4 count has been reported in absolute number and for children CD4 has been reported 
in percentage (14).  
 
1.1.11 Traditional healers and herbal medication use  
 
According to WHO up to 80% of the population in Africa use traditional medicine, with 
variation from area to area (17). Herbal medicines are sometimes used as a primary treatment 
for HIV/AIDS and HIV-related problems (18). The use of traditional/alternative medicine is 
not only centred to Africa. In many high income countries many people have tried traditional 
medicine and the use is increasing rapidly in many parts of the world. (17). In France 75% 
had tried alternative medicine at least once. In Belgium and Canada 38% and 70% had used 
traditional medicine (17). The reason for a broad use of traditional medicine in low income 
countries is its accessibility and affordability (17). The reason for the wide spread of use of 
alternative medicine is that traditional healers are easy to access, many generations in Africa 
have been receiving advice from a traditional healer which give them credibility and 
acceptance among the population (19). The number of HIV-positive patients using herbal 
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medications as primary treatment is unknown (20). It has been shown that herbal medications 
effect the serum levels of antiretroviral medications through their effects on CYP3A4 and 
could contribute to therapy failure (21).  
 
1.1.12 Factors associated with therapy failure 
 
Adherence plays an important role of HIV viral suppression and is associated with therapy 
success with reduced rates of resistance, an increase in survival, improved quality of life and 
prevents the spread of HIV. Factors such as stigma, not having enough emotional support at 
home, little knowledge about ART, resistance developing, poor availability of monitoring 
clinics and lack of medication, effect the adherence negatively (4). Studies made in Tanzania 
have shown that drug resistance to first line ART due to poor medication adherence, increase 
the risk in developing drug resistance to second line ART (22).  
 
1.2 Aim 
 
The aim of the study was to determine the prevalence of antiretroviral treatment failure 
among patients over 18 years monitored at Dodoma Regional Hospital, Tanzania and to 
identify factors associated with therapy failure. 
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2. Material and Methods  
	
2.1 Study design  
	
The study was done as a cross sectional retrospective study of HIV-diagnosed men and 
women followed up clinically at Dodoma Regional Hospital, Tanzania during the period of 
27th of February -15th of March 2017. A questionnaire consisting 39 questions were given to 
the patients. Included questions were age at diagnosis, treatment start, medication and dose, 
specific questions about adherence, difficulties with administration of medicaments, side 
effects, positive effects, presence of HIV-positive family members, socioeconomic status, 
demographic characteristics and distance to hospital, (see appendix). Parts of the 
questionnaire was borrowed from Emelie Thoren’s master thesis, “High adherence to 
antiretroviral treatment despite frequent adverse effects among people living with HIV in 
Dodoma, Tanzania”, and the other questions were new.  
 
The questionnaire was written in English and translated into Swahili.  Information about ART 
regime, ART-start date, CD4 counts and opportunistic infections were collected from the 
patient records that were written in English. Treatment failure was determined by using 
patients’ medical records and following the WHO criteria for clinical and immunological 
treatment failure with some modification. Testing of HIV-viral load were not performed. 
Patients were selected following the inclusion criteria below when attending their scheduled 
appointment at the hospital. If the patient were suitable for the research, the doctor in charge 
of the patient informed about the study and handed over the questionnaire at the end of the 
consultation. An English and Swahili speaking nurse was available for answering any 
questions the patients had about the questionnaire. After completion of the questionnaire, they 
were put in the patient’s medical record and labelled with a number. After labelling the 
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questionnaire data was extracted from the patient’s medical record and afterwards the files 
were returned and questionnaires were saved for data input into an excel file. Patients that did 
not want to participate in the study or that did not fulfil the inclusion criteria were excluded. 
Few patients did not want to participate in the study.  
	
2.2 Pre-testing 
	
Both supervisors involved with the project checked the questionnaires and one of the doctors 
at the hospital translated the final English version into the final Swahili version. Thereafter the 
questionnaire was evaluated on 15 patients and the questions were modified during five test 
days to prevent any misinterpretations. Patients that participated in the test study were not 
included in this study.  
s	
Table	1.	Therapy	failure	definitions	used	in	the	research,	based	on	WHO’s	criteria	for	therapy	failure	
Failure definition Comments 
Clinical  
failure 
Adults and adolescents 
New or recurrent clinical event indicating severe 
immunodeficiency (WHO clinical stage 4 condition)a after 6 
months of effective treatment 
 
The condition must be differentiated from 
immune reconstitution inflammatory syndrome 
occurring after initiating ART 
 
Immunological 
failure 
Adults and adolescents 
CD4 count falls to the baseline (or below)  
or  
Persistent CD4 levels below 100 cells/mm3  
or 
*CD4 count falls with 50% from peak value 
after 6 months of effective treatment 
Without concomitant or recent infection to 
cause a transient decline in the CD4 cell count 
Virological 
failure 
Plasma viral load above 1000 copies/ ml based on two 
consecutive viral load measurements after 6 months on ART, 
with adherence support 
An individual must be taking ART for at least 6 
months before it can be determined that a 
regimen has failed 
*	Added	criteria	to	WHO’s	definition	of	therapy	failure.	
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Table 1 shows the criteria for clinical, immunological and virological failure defined by 
WHO, with some few modifications. To the immunological failure definition, a CD4 count 
fall with 50% from the peak value was added as an alternative way of defining failure.  The 
definition of therapy failure in children has been removed since the study excluded children. 
Severe events of WHO clinical stage 3 were not included as therapy failure in this study.  
 
2.3 Study population 
 
The study population consisted of 93 HIV positive men and women, over 18 years with at 
least 6 months on first line antiretroviral treatment.  Among the patients 77% were women 
and 23% men. Patients were selected by checking the medical records at their regular visit at 
the hospital. If they fulfilled the inclusion criteria the were included in the research and 
offered to participate, otherwise they were excluded together with patients that did not want to 
participate. Few patients did not want to participate, no data on the number of patients 
excluded were collected. Among the studied population 14% had a failing antiretroviral 
treatment.  
 
2.4 Inclusion criteria 
 
Inclusion criteria was HIV-positive patients (age ≥18 years), receiving first line ART for a 
minimum of 6 months. 
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2.5 Statistical methods 
 
2.5.1 Population and data collection 
 
Data collection included primary data from patient records on used drugs, CD4 cell counts, 
opportunistic infections together with a questionnaire. Data was registered into Excel using 
Google Forms and later transferred to SPSS version 24. 
 
SPSS were used to compare patients with successful treatment by using the crosstabulation 
function. Depending on how many variables were analysed, significant differences were 
calculated by using likelihood Ratio or Fischer’s exact test with a significant P-value of 
<0.05. In cases were a significant P-value was found, the two groups were compared with 
odds ratios with 95 % confidence intervals for the underlying factors and outcome variables. 
Patients that did not answer a question were excluded in the analysis.  
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3. Ethics  
	
All participants received information about the study’s purpose and use. Stressing that the 
participation was voluntary and did not affect the treatment if they did not want to participate. 
All personal information was strictly confidential and was only used for the study. No 
personal information was disclosed. Ethical approval was given by the medical coordinator at 
Dodoma Regional Hospital. 
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4. Results 
	
The study population consisted of 93 patients aged 18-70 years and had a mean and median 
age of 44 and 45 years. Among these 23% were male and 77% were female. 
	
4.1 Sociodemographic 
	
Table 2 and 3 present the result of the general question section. There seems to be a tendency 
that a more in the of the group with failing treatment were farmers/peasants (P=0.124). No 
significant difference was found for the other factors regarding occupation, education levels, 
marital status, age and living conditions.  
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Table	2.	Sociodemographic	characteristics	of	the	93	participants	in	the	study	
 Study Population % 
Successful 
treatment % 
Failing 
treatment % Statistics P= 
Sex       Fisher’s Exact Test 
 
0.484 
Male 21 23 17 22 4 31   
Female 71 77 62 78 9 69   
Total 92 100 79 100 13 100   
Percentage of the 
studied population  100  86  14   
         
Marital status       Likelihood  Ratio 0.296 
Married 23 25 20 25 3 23   
Single 20 22 15 19 5 39   
Divorced/Separated 14 15 13 16 1 8   
Widowed 23 25 20 25 3 23   
Cohabiting 3 3 2 3 1 8   
Boyfriend/Girlfriend 10 11 10 13 0 0   
Total 93 100 80 100 13 100   
Percentage of the 
studied population  100  86  14   
         
Occupation       Likelihood Ratio 0.124 
Unemployed 8 9 7 9 1 8   
Employed 12 13 12 15 0 0   
Self-employed/ 
Business 29 32 27 35 2 15   
Student 2 2 1 1 1 8   
Peasant/Farmer 35 39 27 35 8 62   
Retired 5 6 4 5 1 6   
Total 91 100 78 100 13 100   
Percentage of the 
studied population  100  86  14   
         
Education       Likelihood Ratio 0.682 
Never been to school 11 12 10 13 1 8   
Primary school 57 61 49 61 8 62   
Secondary school 20 22 16 20 4 31   
High school 1 1 1 1 0 0   
University/collage 4 4 4 5 0 0   
Total 93 100 80 100 13 100   
Percentage of the 
studied population  100  86  14   
	
	
Table	3.	Age	differences	between	patients	with	successful	treatment	and	failing	treatment.		
 
	
	
 
 Mean age 
Median 
age 
Minimum 
age 
Maximum 
age 
Total study 
population 44.16 44.50 18 70 
Failing 
treatment 41.85 47.00 19 60 
Successful 
treatment 44.54 44.00 18 70 
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4.2 Treatment  
	
The prevalence of therapy failure in the study population was 14%, out of these eight percent 
were diagnosed as clinical failure. The self-reported health status today compared to before 
initiating ART, 61% admitted they were feeling much better. In the group with failing 
treatment 73% had to take their medications two times per day compared to the group with 
successful treatment where 51% took their medication one time per day (n.s). No significant 
differences were found among the results of the treatment section in the questionnaire.  
	
4.3 Economy and accessibility 
	
	
Table	4.	Amount	of	time	patients	spent	traveling	to	the	clinics	
 Time to the clinic 
 
Therapy Less than 30 min 30 min – 1 h 1 – 2 h 3 - 4 h 
 
Total 
Successful 
treatment 
 
Count 27 33 16 3 79 
% 34% 42% 20% 4% 100.0% 
Failing 
treatment 
Count 2 5 2 4 13 
% 15% 38.5% 15% 31% 100.0% 
Total 
Count 29 38 18 7 92 
% 32% 41% 20% 8% 101.0% 
Likelihood 
ratio: 0.034 
	
	
When comparing the time that was spent traveling to the clinics a significant difference was 
found between the groups (table 4). Patients failing ART had in 31% of the cases a travel time 
of 3-4 hours to the clinics, compared to the successful group where only four percent of the 
patients travelled for that long (P=0.034).  
 
Patient with successful treatment had in 87% of the cases low to moderate costs for traveling 
and 13% had high costs. Among the failing group 46% reported high costs. Patients that have 
high traveling costs to the clinics have a 5.74 higher risk of therapy failure compared to 
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patients with low to moderate travel costs, see table 9. 
 
In the study population 91% had never interrupted their medications due to economic reasons, 
there were no significant differences between the groups. Patients in the study population had 
multiple times got the information about the importance of HIV-medications, (81%). 
	
4.4 Health 
	
Smoking	was	not	common	in	the	study	population,	95	%	answered	that	they	did	not	smoke.	
In	the	failing	treatment	group,	none	was	smoking.	No	significant	differences	were	found	
between	the	groups	when	comparing	smoking	and	drinking	habits.		
	
4.5 Social network 
	
In	the	study	population	85%	of	the	patients	had	at	least	one	person	to	talk	to	about	their	
HIV-diagnosis	with	no	significant	difference	between	the	groups.	Stigma	was	the	most	
common	reason	why	people	did	not	want	to	talk	to	others	about	their	HIV-diagnosis	(25%).	
A	fifth	of	the	patients	did	not	have	a	problem	talking	about	their	diagnosis	and	another	17%	
did	not	disclose	their	HIV-status	because	they	did	not	want	people	to	judge	them	and	talk	
about	them.		
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Table	5 Patients	that	received	advice	from	a	traditional	healer	about	their	HIV-treatment	
 
 
 
 
	
	
 
	
	
	
	
	
Table	6	Patients	that received	the	advice	from	a	traditional	healer	to	stop	with	their	HIV-treatment	
 
 
 
 
 
	
	
	
	
	
As illustrated in table 5, seventeen percent of the patients failing treatment had been in contact 
with a traditional healer and received advice regarding their HIV compared to three percent in 
the successful treatment group (P=0.088)  
 
As many as 18% among the patients that were failing their treatment had gotten the advice to 
stop taking their HIV-medication from a traditional healer compared to none in the successful 
group (P=0.014).  
 
 Received advice from a 
traditional healer 
Therapy 
 Yes No 
 
Total 
Successful treatment 
Count 2 74 76 
% 3% 97% 100% 
Failing treatment 
Count 2 10 12 
% 17% 83% 100% 
Total 
Count 4 84 88 
% 5% 96% 100% 
Fisher’s Exact Test  
P= 0.088     
 
Got the advice to stop their 
HIV-treatment 
Therapy Yes No 
 
Total 
Successful treatment 
Count 0 77 77 
% 0.0% 100.0% 100.0% 
Failing treatment 
Count 2 9 11 
% 18% 82% 100.0% 
Total 
Count 2 86 88 
% 2% 98% 100.0% 
Fischer’s Exact Test  
P=0.014     
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Five percent of the study population admitted they had taken ART and herbal medications at 
the same time. In the failing treatment group eight percent we.re using both herbal 
medications and ART. The use in the successful group was four percent (n.s).  
	
4.6 Contact with partners 
	
In	the	group	with	failing	patients	15%	had	a	sexual	relationship	with	more	than	one	person	
and	in	the	successful	group	five	percent	of	patients	had	sex	with	more	than	one	person.	
	
		
Table	7.	Number	of	patient	that	used	a	condom	last	time	they	had	sex	with	a	temporary	partner	
 Used a condom last time they had 
sex with temporary partner 
Therapy Yes No Total 
Successful treatment 
 
Count 24 7 31 
%  77.% 23% 100% 
Failing treatment Count 2 4 6 
%  33% 67% 100% 
Total Count 26 11 37 
%  70.% 30% 100% 
Fischer’s Exact Test 
P=0.051     
	
	
A tendency towards a more frequent treatment failure was found among patients that did not 
use condom last time they had sex with a temporary partner (P=0.051), table 7. 
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4.7 CD4 cell counts 
 
 
Table	8.	CD4	cell	counts	of	the	patients		
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
In	total	of	92	CD4	values	used	in	the	study	for	determining	therapy	failure,	75%	were	over	
one	year	old.	
	
4.8 Risk of failing antiretroviral treatment 
	
	
Table	9.	Factors	associated	with	therapy	failure.	
 
 
 
*	ART	(Antiretroviral	treatment).		
	 	
 Initial 
CD4 
Last 
CD4 
Study population   
Mean 173.11 460.96 
Median 125 448.5 
   
Failing treatment   
Mean 199.69 192.38 
Median 160.00 146.00 
   
Successful 
treatment 
  
Mean 168.79 505.15 
Median 122.00 462.00 
 
 OR (95% CI) P-value 
High transport costs 5.74 (1.60-20.6) 0.007 
Long time to the clinic 11.26 (2.17-58.6) 0.0040 
Advice from a traditional healer to 
stop *ART 40.8 (1.82-914) 0.019 
Advice from a traditional healer 7.4 (0.94-58.5) 0.058 
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actors	associated	with	therapy	failure	are	listed	in	table	9.	High	transport	costs	gave	a	5.74	
times	higher	risk	of	therapy	failure.	Long	transport	time	to	the	clinic	gave	a	11.26	times	
increased	risk	of	therapy	failure.	Receiving	advice	from	a	traditional	healer	gave	almost	41	
times	higher	risk	of	therapy	failure	compared	to	a	patient	that	did	not	receive	any	advice	of	
stopping	their	treatment.		
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5. Discussion  
	
The findings of this study show that factors such as long travels to the hospitals, high 
transport costs and advice from traditional healers could increase the risk of antiretroviral 
therapy failure.  
	
5.1 Factors associated with therapy failure 
	
It is not surprisingly that a traditional healer’s advice to stop with the ART was the biggest 
risk factor for failing treatment. Many people in Africa and Tanzania seek for advice and care 
from traditional healers. A study of 442 HIV-infected patients, aged 18-64 years at 
Kilimanjaro Christian Medical Centre showed that as many as 56% of the patients had visited 
a local healer in the city of Loliondo. Five percent of the patients visiting the healer had 
gotten the device to stop ART. A significant but not a permanent decline in ART adherence 
was found among the patients that had been in contact with the healer (20). Another study that 
included 4489 patients from Tanzania, Uganda and Zambia showed that visiting a traditional 
healer, screening positive for alcohol abuse and greater levels of internalized stigma were 
actors significantly associated with incomplete adherence (23). It is well known that a 
decrease in adherence is associated with therapy failure (24). In our study two percent got the 
advice to stop with HIV-treatment due to a traditional healer’s advice. A reason for traditional 
healers’ big impact in Africa is the fact that spiritual beliefs have been influencing the culture 
for generations and herbal treatment is an accepted method for treatment.  Some people 
choose to visit a traditional healer before going to a medical doctor. Traditional healers have a 
lot of support among the population and for some patients seeking them consider the 
traditional healers to be more reliable than medical doctors. For the doctors working in the 
hospitals the lack of trust can be an issue since the patients aren’t always following the 
prescriptions or hiding the fact that they use herbal medications together with their ART. The 
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space between medical doctors and patients is something that could be improved by involving 
traditional healers in the HIV-care and providing them with education about HIV and when to 
encourage patients to seek a medical doctor.  
 
Religion could also be a factor among patients falling treatment since religion is strongly 
influencing the society of Tanzania. In a study made in Arusha and Babati region 438 patients 
belonging to Catholic, Lutheran, and Pentecostal churches were given a questionnaire to 
examine the relation between religious beliefs and HIV-stigma, disclosure and attitude 
towards ART. The results showed that HIV-stigma was strongly associated with religious 
beliefs. HIV was considered as a punishment from God (P=0.01) (25). As high as 80.1% of 
the participants answered HIV could be cured by prayer. Unfortunate we did not look at 
religion and possible association with antiretroviral therapy failure in our study.  
 
HIV-stigma is a big problem with HIV treatment and could explain why patients seek 
alternative medicine (26). Going to the clinics for doctor appointments or collecting HIV-
medications could make people in the surroundings curious about their HIV-status. Many 
patients get their HIV-medication at the clinics and immediately after leaving the doctors 
room they go to the rest rooms to through away the packages so that nobody sees the HIV-
medications. Some patients even take out the pills from the containers and put it in a small 
bag, bottle etc. Bathrooms at the clinic were full of containers and packages. 
Another problem is the fact that some people fear medications and turn to traditional healers 
and herbal medications (17). Some patients on ART have problems with adverse effects a 
number of these patients stop taking their HIV-medications and turn to traditional healers and 
herbal medication believing that the herbal medications help them since they are not feeling 
the side effects form the ART.  A research made in South Africa followed 222 patients that 
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reached out to a traditional healer that had been trained in HIV/STI, prevention and care. 
There were 18 HIV-positive patients (8.1%) and out of these 8 (44%) were using traditional 
medicine and ART at the same time (27). In this study, a total of five percent of the studied 
population admitted they were using herbal medication and ART at the same time. As 
mentioned in the background, it has been shown that herbal medications effect the serum 
levels of antiretroviral medications through their effects on CYP3A4 and could contribute to 
therapy failure (21). There are not so many studies made on herbal medications and the 
effects of the HIV-care and therapy failure (28). This could be interesting to continue 
investigating.  
 
The study shows that high transport costs and a long time spent traveling to the hospitals 
increase the risk of therapy failure. Patients that have to travel for hours to the treatment 
clinics have to plan their trips in advance. Traveling 4h one way to the clinic the patients need 
a full day for the appointments. This might affect their work, economy and it could raise 
questions about the patient’s absence in villages/cities. Some patients choose to get their HIV-
care in other cities since they fear exclusion from the society if they receive care in their own 
city. There is a possibility that stigma is the reason why some patients decide to get their 
medications in other cities. A possible explanation why patients with high transport costs and 
long travel time are more often associated with therapy failure could be due to poor 
adherence. In case that medications are out of stock, or the patients miss their appointments it 
is likely that it is harder for patients living far away from the clinics to find time to get their 
medications and keep good adherence. Even though Tanzania have been fighting stigma and 
discrimination of people living with HIV there is still a lot to be done. In our study 25% of the 
population did not want to disclose their HIV-status because of stigma. 
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5.2 Contact with partners 
 
On the question if the patients used a condom last time they had sex with a temporary partner, 
the results show that there is a tendency that patients that did not use condom had a higher 
risk of treatment failure. Among patients failing treatment 67% admitted they did not use a 
condom last time they had sex with a temporary partner, these patients risk transmitting HIV-
infection. Only six out of thirteen patients failing treatment answered this question, the rest 
were excluded since they did not have a partner/ did not remember if they used protection. It 
would be interesting to know why patients with treatment failure prefer not to use a condom 
when having sex with a temporary partner.  
	
5.3 Sociodemographic 
	
In the city of Dodoma the population are estimated to consist of 51% men and 49 % women 
(29). 
 
Our study had 23% male participants and 77% female, no significant difference was found 
between the failing and successful groups. An explanation to the fact that the majority of the 
patients were women could be that some male patients were ashamed of going to the 
appointments to get their medications. Instead they would send their wives / partners to get it 
for them and since the men did not show up they could not be included in the research. In a 
study of HIV-positive patients with immunological failure of first-line and switch to second-
line antiretroviral therapy in Tanzania showed that being a male was a risk factor for therapy 
failure (16). We found no associations between sex therapy failure. 
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5.4 Methodological considerations 
	
5.4.1 Strengths of the study 
	
Using a questionnaire in this study made it possible to ask the patients private questions that 
could have been hard to ask when interviewing patients. The questions used in the research 
concerned many different areas and this resulted in a lot of valuable information. For patients 
that had difficulties reading or understanding the questions a secretary was available to assist. 
Translations were made by an English and Swahili speaking doctor and checked later checked 
in the testing phase. Determination of therapy failure was done by the same person to avoid 
bias.  
	
5.4.2 Limitations of the study 
	
The study was performed as an explorative retrospective study. The best way to look for 
potential factors associated with therapy failure would have been to do a case-control study as 
the original plan was. Due to logistic reasons a case-control study was not possible to do.  
 
The HIV clinic had from time to time over 100 patients per day and sometimes patients were 
sitting close to each other or the treating doctor when filling in the questionnaires. This could 
have affected the answers given, since some patients tend to answer what they think is correct 
to answer. Since 100% privacy could not be guaranteed it is possible that some patients felt 
ashamed and wrote down another answer rather than the real answer.  
 
We investigated many factors that could influence the therapy and there is a risk of getting 
false significance and therefore the results of the research should be used with this in 
concerned.  
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Another limitation is the fact that the studied population consisted of 93 patients which gives 
the study a lower power. To achieve greater statistical power, it would have been necessary to 
extend the study population and include more patients and if possible more hospitals in the 
city.  
 
Furthermore, it is likely that the study population was not fully representing the HIV-
population of Dodoma, since a small amount of men were included and patients that was very 
ill and potentially failing treatment were probably home or at the hospital getting treatment 
for severe infections.  
 
To be able to determine a prevalence of therapy failure at Dodoma regional hospital the 
number of patients put on treatment, patients remaining on treatment, drop-out patients and 
the number of deaths in HIV/AIDS would have to be known and we did not have access to 
this information in this study. 
 
The original plan was to use virological failure for determining therapy failure. Unfortunate 
this was not possible since the use of viral testing had not yet fully started. Instead we used 
WHO’s criteria for immunological therapy failure and modified it a bit. A systematic review 
found that current WHO clinical and immunological failure had low sensitivity and positive 
predictive value for identifying patients with virological failure (13). Plan B was to use the 
updated CD4 values to determine whether patients were failing or not. Unfortunate 75% of 
the studied population had CD4-values that was more than one year old and this made it hard 
to determine whether the patients were failing their treatment at the time of the visit. 
Therefore, treatment failure was decided at the date last CD4 was measured.  
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Definition of clinical failure was only used once since the opportunistic infections and all data 
was collected from hand-written medical records of varied quality. In some cases, medical 
records were very old and information about the treatment was missing.  
 
In the future, it would be of interest to further investigate the effects of alternative medicine 
on HIV- therapy in Dodoma. The Reliability of diagnosing treatment failure at the hospital 
using CD4 counts together with the clinical definition, could be compared to viral load testing 
in future studies.  
6. Conclusions  
	
	
High transport costs and long time spent traveling to get HIV-care increase the risk of therapy 
failure and could possibly be prevented by improved the accessibility. 
 
 A traditional healer’s advice to stop ART was associated with a higher risk of therapy failure. 
Education and collaboration with traditional healers could be of interest to prevent that 
patients from stop using ART. 
 
 Some patients failing treatment admitted not using a condom when having sex with a 
temporary partner. It is important to educate patients but also the whole population with the 
risks of HIV-transmission and unprotected sex.  
 
A majority of the patients at the treatment facilities are women. It is of importance to attract 
more men to the clinics to offer an equal HIV-care. 
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Stigma is still highly present I Tanzania. A more open community and acceptance for people 
living with HIV would be valuable for further progress of HIV-care. There is still more 
research to be done investigating the effects of herbal medications and antiretroviral 
treatment. 
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7. Populärvetenskaplig sammanfattning 
	
Terapisvikt vid första linjens behandling med bromsmediciner, 
bland HIV-patienter vid det regionala sjukhuset i Dodoma, 
Tanzania. 
 
Icke-fungerande HIV-behandling resulterar till ökade virusmängder, sämre immunförsvar, 
försämrad sjukdomsbild och ökad smittsamhet. Årligen dör 36 000 människor i AIDS-
relaterade sjukdomar i Tanzania och behandling med bromsmediciner är livsnödvändig.  
 
I en del afrikanska länder uppskattas det att ca 80% av invånarna har varit i kontakt med 
traditionella helare och alternativ medicin. Studier har visat att naturläkemedel ibland sänker 
den verksamma mängden HIV-läkemedel i blodet vilket kan försämra HIV-behandlingen så 
viruset får möjlighet att bli fler i antal.  
 
HIV är inte bara ett hälsoproblem utan är också ett socioekonomiskt problem och påverkar 
den ekonomiska tillväxten negativt. Diskriminering av HIV-positiva patienter är en av de 
större utmaningarna i kampen mot HIV.  
 
Vid användning av olika läkemedelskombinationer mot HIV är det viktigt att ha förståelse för 
olika faktorer som kan bidra till försämrad behandling. Vi ställde oss frågan: vilka faktorer 
bidrar till försämrad behandling på det regionala sjukhuset i Dodoma, Tanzania?  
 
Studien var en retrospektiv tvärsnittsstudie av 93 HIV-positiva män och kvinnor som följdes 
upp på det regionala sjukhuset i Dodoma, Tanzania. Den studerade populationen delades in i 
två grupper, de med icke-fungerande behandling och de med fungerande behandling. Alla 
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HIV-positiva patienter över 18 år som hade använt första kombinationerna av antivirala 
läkemedel under minst 6 månader, inkluderades i studien. Icke fungerande behandling 
definierades enligt World Health Organization’s, (WHO’S) kriterier för icke-fungerande 
behandling.  
 
Andelen som hade icke-fungerande behandling bland de patienter som följdes på sjukhuset i 
Dodoma var 14%. Hela 67% av de som hade icke-fungerande behandling uppgav att de inte 
använde något skydd när de hade sex med en tillfällig partner.  
 
Vår studie visade att höga resekostnader och lång transporttid till kliniken ökade risken för att 
drabbas av icke-fungerande behandling med ca 6 respektive 11 gånger. Ökad tillgänglighet av 
behandlande kliniker och bättre transportmöjligheter är ett sätt att bemöta höga resekostnader 
och längre transporttider.  
 
Den allra största riskökningen såg vi hos patienter som hade fått rådet av en traditionell helare 
att sluta ta sina läkemedel, risken att drabbas av icke-fungerande behandling var hela 41 
gånger förhöjd. Allmänna råd från en helare avseende patienternas HIV-behandling ökade 
risken att drabbas av icke-fungerande behandling med ca 7 gånger.  
 
I Tanzania är förtroendet för traditionella helare stort, ibland större än för vanliga läkare. 
Helare har stort inflytande och bör i högsta grad involveras i kampen mot HIV/AIDS. Genom 
att utbilda helare om HIV och naturläkemedels negativa effekter på HIV-behandling skulle de 
kunna användas i kampen mot HIV. Helare skulle kunna samarbeta med läkare, sida vid sida. 
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Appendices 
	
Questionnaire  
	
My name is Alisa and I am studying medicine in Sweden. This questionnaire is a part of my 
master thesis where I will examine how the HIV treatment is working here at the hospital in 
Dodoma. The questionnaire concerns different areas for example HIV treatment that you 
undergo, general questions and questions about your living conditions. 
 
Participation in the study is voluntary and confidential. You can choose to leave the study 
without any specific reason. Care and treatment offered to you will be the same weather you 
choose to participate in the study or not. Participation in the study is valuable and helpful 
when it comes to understanding more about the factors that contribute to therapy failure.  
 
I hope that you find this interesting and that you want to participate in the research.  
 
Thank you! 
 
Instructions:  
Please tick the boxes for the appropriate answer. For some questions, more than one 
alternative can be chosen. Where a longer answer is required, please fill in your answers in 
the space provided. 
		
A.	General	questions	
1.	Age:	_______	years	 	
2.	Level	of	education:	
o Never	been	to	school	
o Primary	school	
o Secondary	school	
o High	school	
o University/College	
3.	Occupation:	
o Unemployed	
o Employed	
o Self-employed/business	
o Student	
o Peasant/	farmer	
o Retired	
4.	Marital	status:	
o Married	
o Single	
o Divorced/Separated	
o Widowed	
o Cohabiting	
o Boyfriend/girlfriend	
5.	Living	conditions:	
o Own	house	
o Rented	house/apartment	
o No	stable	place	to	live	
B.	Treatment	
6.	What	is	the	main	reason	for	taking	your	HIV	
drugs?	
o To	get	cured	from	HIV	
o To	avoid	getting	symptoms	of	HIV	
o The	doctor	tells	me	to	take	the	medicine	
o To	live	longer	
	
7.	Compared	to	before	you	started	the	treatment,	
how	would	you	describe	your	health	status	now?	
o Much	worse	
o Worse	
o The	same	
o Better	
o Much	better	
8.	Have	you	experienced	any	of	the	following	
symptoms	the	last	6	months?	(you	may	choose	
several	options)	
o Nausea	
o Vomiting	
o Diarrhea	
o Abdominal	pain	
o Rashes/skin	lesions	
o Nightmares	
o Problems	to	sleep	
o Dizziness	
o Reduced	sensibility/numbness	in	arms	or	
legs	
o Fat	loss	in	arms,	legs	or	face	
o Severe	weight	loss	
o Muscle	pain/joint	pain	
o Other__________________	
o No	bad	symptoms	
9.	How	many	times	per	day	do	you	take	your	HIV	
drugs?	
o 1	times	a	day	
o 2	times	a	day	
		
o 3	times	a	day	
10.	How	many	pills	for	HIV	treatment	do	you	take	
daily	_______pills	
11.	Have	you	at	any	time	not	taken	your	medicine?	
o Yes,	many	times	
o Maybe	some	time	
o No,	never	
12.	In	the	past	4	weeks	how	many	times	did	you	not	
take	your	medication	as	prescribed?	
o _______times	
13.	If	you	didn´t	take	your	medication	at	any	point,	
what	was	the	reason?	(You	may	choose	several	
reasons)	
o Simply	forgot	
o Side	effects(please	
specify)_____________________	
o Did	not	have	enough	pills	at	home	
o Did	not	have	time	to	get	new	pills	
o Did	not	have	enough	money	to	get	new	pills	
o Did	not	have	access	to	a	clinic	where	I	could	
get	the	pills	
o Other	reason_________________	
14.	Are	you	keeping	your	HIV-medications	in	the	
original	package/tin?	
o Yes	I	keep	my	HIV	medication	in	the	original	
container	
o No	I	do	not	keep	my	HIV-medications	in	the	
original	container(please	specify	how	you	
keep	your	HIV-medication):	
_______________________________	
_______________________________	
C.	Accessibility,	availability,	Economy	
15.	How	long	time	did	you	travel	to	get	to	the	
clinic?	
o Less	than	30	minutes	
o 30	minutes	–	1	hour	
o 1	hour	–	2	hours	
o 3	hours	-	4	hours	
o More	than	4	hours	
16.	How	big	are	the	economic	costs	of	travel	to	the	
clinic	for	you?	
o Not	mentionable	
o Low	
o Moderate	
o High	
o Not	bearable	
17.	Have	you	ever	let	down	your	medicine	due	to	
economic	consequences?	(For	example	costs	to	get	
to	the	clinic,	costs	to	get	the	pills,	have	to	stay	
home	from	work	etc.)	
o Yes,	often	
o A	few	times	
o No	never	
18.	How	is	the	availability/access	to	the	HIV-clinic?	
o It	is	easy	to	contact	the	clinic	and	get	a	visit	
there	when	I	need	to	
o It	is	hard	to	get	a	visit	and	to	contact	the	
clinic	
19.	A.	Since	the	start	of	your	HIV-treatment	have	
you	ever	done	any	of	the	following?	(You	may	
choose	several	options)		
o Stopped	working	
	
o Changed	work		
	
o Traveled	to	another	city	to	get	the	HIV-
medication	
	
o Moved	to	another	city	
	
o Other_____________________	
	
o No,	I	did	not	have	to	do	any	of	the	
alternatives	above.		
D.	Knowledge	of	HIV	and	HIV	drugs	
		
20.	Are	there	any	ways	to	cure	HIV/AIDS?	
o Yes	
o No	
o I	don´t	know	
21.	If	you	don´t	take	the	HIV	drugs	continuously,	
may	any	of	the	following	occur	from	this?	(you	may	
choose	several	options)	
o The	symptoms	of	HIV	may	return/increase	
o The	HIV	drugs	can	stop	working	
o You	can	transmit	HIV	to	others	more	easily	
o Nothing	will	happen	
o I	will	feel	better		
o Other	
_______________________________	
_______________________________	
22.	Have	you	got	information	about	the	importance	
of	taking	the	HIV	drugs	regularly	and	why	it	is	
important?	
o Yes,	multiple	times	with	detailed	
information	
o Yes,	a	few	times	
o Yes,	but	only	one	time	when	I	started	
treatment	
o No,	I	never	got	the	information	
o I	don´t	know	
E.	Health	
23. Have you had any of the following? (you may 
choose several options) 	
o Chest	Pain			
o Irregular	heart	beat		
o Tuberculosis		
o Kidney,	bladder	or	urinary		problems		
o Liver	disease	–	yellowness		
Jaundice		
o Anemia		
24.	Do	you	smoke?	
o Yes		
o No		
o No	but	I	have	been	smoking	in	the	past	
25.	Describe	your	smoking	habits:	
o Daily	(please	specify	how	many	cigarettes	
per	day)	
____________________	
o 4	or	more	times	a	week	
o 2-3	times	a	week	
o 2-4	times	a	month	
o monthly	or	less	
o I	don’t	smoke.		
26.	How	often	do	you	have	a	drink	
containing	alcohol?	
	
o Daily	(please	specify	how	many	alcoholic	
drinks	per	day)	
____________________	
o 4	or	more	times	a	week	
o 1-3	times	a	week	
o 2-4	times	a	month	
o monthly	or	less	
o I	don’t	drink	
	
F.	Social	network	
	
27.	Is	there	a	person	you	can	turn	to	if	you	need	
support	or	somebody	to	talk	to?	
o Yes	I	have	many	people	I	can	talk	to		
o Yes	I	have	a	few	people	I	can	talk	to		
o Yes	I	have	one	person	I	can	talk	to		
		
	
o No	I	do	not	have	anyone	to	talk	to		
	
28.		Did	you	tell	anyone	about	your	HIV-
diagnosis?	(You	may	choose	several	options):	
	
o Yes,	my	partner		
o Yes,	a	family	member		
o Yes,	my	mother		
o Yes,	my	father		
o Yes,	my	sister		
o Yes,	my	brother		
o Yes,	my	daughter		
o Yes,	my	son		
o Yes,	several	family	members		
o Yes,	a	friend		
o Yes,	a	couple	of	friends			
o Nobody	in	my	family	knows	about		 my	HIV-diagnosis		
o My	partner	does	not	know	about	my	HIV-diagnosis		
o None	of	my	friends	know	about	my		 HIV-diagnosis		
o Nobody	but	me	and	the	health	care			 workers	know	about	my	HIV-		 diagnosis			
29.	What	is	the	reason	for	not	telling	people	
you	know	about	your	HIV-diagnosis?	
	
o 	I	do	not	have	a	problem	talking	about		 my	HIV-diagnosis	
	
o It	is	private		
o I	do	not	want	people	to	feel	sorry	for			 me		
o I	do	not	want	people	to	judge	and	talk		 about	me	
	
o I	think	it	could	affect	me	Negatively	(please	specify	in	what	way):									 	___________________________________________			 	___________________________________________		
o Stigma		
o Other(please	describe):______________________________		
30.	Have	you	during	your	HIV-treatment	
received	any	HIV-treatment	advice	from	a	
traditional	healer?		
o Yes		
o No		
31.	Have	you	ever	stopped	using	your	HIV-
medications/changed	the	way	you	use	your	
HIV-treatment	due	to	your	traditional	healer’s	
advice?	
	
o Yes		
o No		
32.	Have	you	ever	taken	any	herbal	medication	
together	with	your	HIV-medicine?	
	
o Yes		
o No		
33.	Are	you	currently	using	any	herbal	
medications	together	with	your	HIV-
medication?		
o Yes		
o No		
G.	Contact	with	partners	
34.	Do	you	know	your	partner’s	HIV	status?	
o Yes,	positive	
o Yes,	negative	
o No,	I	don’t	know	
o I	have	no	current	sexual	partner.		
		
35.	Do	you	have	sexual	relationships	with	more	
than	one	partner?	
o Yes	
o No	
36.	How	many	sexual	partners	do	you	have?	(please	
specify	with	a	number)	
o No	partner	
o 1	partner	
o 2	partners	
o 3	partners	
o 4	partners	or	more	
37.	Do	you	use	condom	during	sex	with	your	
ordinary	partner?	
o Yes,	always	
o Most	of	the	times	
o Not	very	often	
o No,	never	
o I	have	no	partner	
38.	Do	you	use	condom	during	sex	with	your	
temporary	partner?	
o Yes,	always	
o Most	of	the	times	
o Not	very	often	
o No,	never	
o I	have	no	partner	
39.	The	last	time	you	had	sex	with	your	temporary	
partner,	did	you	use	a	condom?	
o Yes	
o No	
o I	do	not	remember	
o I	have	no	temporary	partner	
o I	do	not	use	condom	at	all	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
Medical records 
 
AN: Sex 
Male / Female 
 
Date of birth (ddmmyy)_____ 
 
Date confirmed HIV (ddmmyy) ______ 
 
ART- start date (ddmmyy)_____ 
 
ART prescribed _____ 
 
ART Reason _____ 
 
Since treatment start how many times 
has the patient changed ART regime 
____ 
 
Date (ddmmyy) first time ART was 
changed ______ 
 
Previous treatment ______ 
 
ART change reason _____ 
 
Date previous treatment 
(ddmmyy)_____ 
 
Nutritional status ______ 
 
Initial CD4______ 
 
Date (ddmmyy) Initial CD_______ 
 
Last CD4______ 
 
Date (ddmmyy) last CD4____ 
 
Lowest CD4 ______ 
 
Date lowest CD4 ______ 
 
Highest CD4 ______ 
 
Date (ddmmyy) Highest CD4____ 
 
Any opportunistic infections____ 
 
Number of opportunistic 
infections_____ 
 
Functional status (start) _____ 
 
OI treatment/prophylaxis and relevant 
CO-medications _____ 
 
Follow up status _____ 
 
BN: Therapy____ 
Successful / Failing  
 
WHO clinical stage (1-4) (today) ____ 
 
Time from ART-start to first therapy 
change ____ 
 
Time from positive HIV result to ART- 
start _____ 
 
Years on treatment _____ 
 
Last CD4 taken within 1 year? ____ 
 
Transferred patient? ____ 
